Filing Details

Accession Number:
0001209191-19-034851
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-05 17:41:11
Reporting Period:
2019-06-03
Accepted Time:
2019-06-05 17:41:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1717452 Odonate Therapeutics Inc. ODT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1178579 C Kevin Tang 4747 Executive Drive
Suite 510
San Diego CA 92121
Chief Executive Officer Yes Yes Yes No
1191935 Tang Capital Partners Lp 4747 Executive Drive
Suite 510
San Diego CA 92121
No No Yes No
1232621 Tang Capital Management Llc 4747 Executive Drive
Suite 510
San Diego CA 92121
No No Yes No
1495904 G John Lemkey 4747 Executive Drive
Suite 510
San Diego CA 92121
Chief Operating Officer No Yes No No
1759910 S Michael Hearne 4747 Executive Drive
Suite 510
San Diego CA 92121
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-03 7,859 $22.16 13,093,897 No 4 P Indirect By LP
Common Stock Acquisiton 2019-06-03 7,427 $22.86 13,101,324 No 4 P Indirect By LP
Common Stock Acquisiton 2019-06-04 34,714 $24.92 13,136,038 No 4 P Indirect By LP
Common Stock Acquisiton 2019-06-04 4,236 $24.99 13,140,274 No 4 P Indirect By LP
Common Stock Acquisiton 2019-06-05 9,972 $25.14 13,150,246 No 4 P Indirect By LP
Common Stock Acquisiton 2019-06-05 29,484 $26.11 13,179,730 No 4 P Indirect By LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
No 4 P Indirect By LP
Footnotes
  1. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $21.48 to $22.47. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 7 herein.
  2. The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management,LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares ofcommon stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authorityto vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
  3. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $22.48 to $23.00.
  4. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.41 to $25.00.
  5. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.91 to $25.00.
  6. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $24.76 to $25.75.
  7. The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $25.76 to $26.50.